Exelixis (EXEL) Bullish View Reiterated at Leerink Following Positive CABOSUN Data

October 10, 2016 7:40 AM EDT
Get Alerts EXEL Hot Sheet
Price: $18.03 -2.59%

Rating Summary:
    6 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 9
Trade EXEL Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and $15 price target on Exelixis (NASDAQ: EXEL) after the company reported positive CABOSUN data to be presented as a late breaker at ESMO later today.

Schmidt commented, "Overall, the data looks clearly statistically and clinically significant in terms of p-value and hazard ratio and we would expect a high approval probability in moderate and poor risk front-line treatment of renal cell carcinoma (RCC), representing roughly 80% of the annual incidence based on the published literature."

For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.

Shares of Exelixis closed at $12.95 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment